Does brigatinib require long-term and lifelong medication?

How long you should take Brigatinib (Brigatinib) and whether it needs to be used for life depends entirely on the patient's specific condition, response to treatment, and whether drug resistance develops. As a targeted drug for non-small cell lung cancer (NSCLC) with positive ALK (anaplastic lymphoma kinase) gene mutations, brigatinib (Brigatinib) 's treatment strategy and medication duration show obvious individual differences.

Normally, the treatment cycle of brigatinib is not a lifetime, but can be flexibly adjusted according to the actual situation of the patient. The duration of drug use is closely related to the patient's response to the drug, disease control status, and the emergence of drug resistance. On the premise that the disease is effectively controlled and the side effects are bearable, patients may need to take brigatinib (brigatinib) for a long time to maintain the stable state of the disease and prevent recurrence.

However, over time, it is possible for patients to develop resistance to brigatinib . The time when drug resistance appears varies from person to person, but is usually around 6 months to 1 years, although it may be earlier or later. Once drug resistance appears, the efficacy of brigatinib will be greatly reduced, and it may be necessary to change the drug or adjust the treatment plan. Faced with resistance to brigatinib, discontinuing the drug and moving to other treatment options, such as trying other types of targeted agents, chemotherapy, or immunotherapy, may be a reasonable option.

Long-term use of brigatinib may cause side effects such as high blood sugar, rash, and lung problems. Doctors will adjust the dose or perform symptomatic treatment based on the patient's tolerance and the severity of side effects. If side effects are severe and difficult to effectively control, discontinuation of the drug or adjustment of the treatment plan may be considered.

In summary, there is no fixed answer to whether brigatinib needs to be taken for life. The duration of treatment should be flexibly determined based on the patient's specific condition and response to treatment. In most cases, brigatinib is used as long-term treatment to maintain disease control, but the emergence of resistance and side effects may affect the decision to continue use. Once resistance develops or side effects become severe, patients may need to discontinue the drug and switch to other treatments. Therefore, regular follow-up visits and close monitoring of the condition are important in deciding whether to continue using brigatinib (brigatinib) is of vital importance.